

Nana-Goar V Pogosova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4390341/publications.pdf>

Version: 2024-02-01

40
papers

9,193
citations

304368

22
h-index

182168

51
g-index

53
all docs

53
docs citations

53
times ranked

12604
citing authors

#	ARTICLE	IF	CITATIONS
1	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330.	13.9	1,745
2	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2019, 394, 121-130.	6.3	1,625
3	Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. <i>Lancet, The</i> , 2016, 388, 761-775.	6.3	1,414
4	EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 636-648.	0.8	772
5	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 219-229.	6.3	651
6	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 824-835.	0.8	558
7	Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 664-681.	0.8	486
8	Cardiac rehabilitation in Europe: results from the European Cardiac Rehabilitation Inventory Survey. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 410-418.	3.1	403
9	Psychosocial aspects in cardiac rehabilitation: From theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1290-1306.	0.8	227
10	Design and baseline characteristics of participants in the <sc>R</sc>esearching cardiovascular <sc>E</sc>vents with a <sc>W</sc>eekly <sc>IN</sc>cretin in <sc>D</sc>iabetes (<sc>REWIND</sc>) trial on the cardiovascular effects of dulaglutide. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 42-49.	2.2	160
11	Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 2007-2018.	0.8	153
12	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1027-1035.	0.8	133
13	Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. <i>Cardiovascular Diabetology</i> , 2015, 14, 133.	2.7	101
14	Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study. <i>Lancet, The</i> , 2018, 391, 2019-2027.	6.3	96
15	Psychosocial risk factors in relation to other cardiovascular risk factors in coronary heart disease: Results from the EUROASPIRE IV survey. A registry from the European Society of Cardiology. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1371-1380.	0.8	94
16	Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 370-379.	0.8	83
17	Exercise-based cardiac rehabilitation in twelve European countries results of the European cardiac rehabilitation registry. <i>International Journal of Cardiology</i> , 2017, 228, 58-67.	0.8	70
18	Assessing the Global Burden of Ischemic Heart Disease: Part 1: Methods for a Systematic Review of the Global Epidemiology of Ischemic Heart Disease in 1990 and 2010. <i>Global Heart</i> , 2012, 7, 315.	0.9	63

#	ARTICLE	IF	CITATIONS
19	Simplifying the audit of risk factor recording and control: A report from an international study in 11 countries. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1202-1210.	0.8	42
20	Poor adherence to lifestyle recommendations in patients with coronary heart disease: results from the EUROASPIRE surveys. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 383-395.	0.8	40
21	Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 328-339.	0.8	27
22	Ischaemic heart disease in the former Soviet Union 1990â€“2015 according to the Global Burden of Disease 2015 Study. <i>Heart</i> , 2018, 104, 58-66.	1.2	26
23	Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey. <i>International Journal of Cardiology</i> , 2018, 272, 20-25.	0.8	24
24	Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study. <i>European Journal of Epidemiology</i> , 2019, 34, 247-258.	2.5	22
25	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. <i>European Heart Journal</i> , 2021, 42, 2565-2573.	1.0	17
26	Can level of education, accreditation and use of databases in cardiac rehabilitation be improved? Results from the European Cardiac Rehabilitation Inventory Survey. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 143-150.	0.8	14
27	The use of HeartQoL in patients with coronary heart disease: Association with risk factors and European reference values. The EUROASPIRE IV study of the European Society of Cardiology. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1174-1186.	0.8	14
28	Anger or emotional upset and heavy physical exertion as triggers of stroke: the INTERSTROKE study. <i>European Heart Journal</i> , 2022, 43, 202-209.	1.0	14
29	Sequelae of COVID-19 at long-term follow-up after hospitalization. <i>Rational Pharmacotherapy in Cardiology</i> , 2022, 18, 118-126.	0.3	13
30	Secondary prevention in patients with coronary artery disease in Russia and Europe: results from the Russian part of the EUROASPIRE V survey. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2020, 19, 2739.	0.4	9
31	Governmental efforts for cardiovascular disease prevention efforts in the Russian Federation. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 67, S48-S54.	0.7	8
32	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 786-795.	1.4	6
33	Hypertensives in Russia are interested in a healthier lifestyle: results of the RELIF multicenter study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 224-232.	3.1	5
34	Potential for optimizing management of obesity in the secondary prevention of coronary heart disease. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, , .	1.8	5
35	Costs associated with cardiovascular disease create a significant burden for society and they seem to be globally underestimated. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1147-1149.	0.8	3
36	Alcohol consumption patterns across Europe and adherence to the European guidelines in coronary patients: Findings from the ESC-EORP EUROASPIRE V survey. <i>Atherosclerosis</i> , 2020, 313, 35-42.	0.4	3

#	ARTICLE	IF	CITATIONS
37	Pharmacoeconomic study of rivaroxaban and acetylsalicylic acid combination use in patients with coronary artery disease and/or peripheral artery disease. Russian Journal of Cardiology, 2019, , 76-86.	0.4	2
38	New treatments and technologies in cardiac rehabilitation programs. Voprosy Kurortologii, Fizioterapii, i Lechebnoi Fizicheskoi Kultury, 2022, 99, 50.	0.1	1
39	Factors affecting the uptake of national practice guidelines by physicians treating common CVDS in out-patient settings. Kardiologiya, 2022, 62, 33-44.	0.3	1
40	Social Network-Based Digital Stroke Prevention: Opportunities, Results and Prospects. Rational Pharmacotherapy in Cardiology, 2021, 17, 696-701.	0.3	0